Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: AMRN stock price vs MRK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRK's multiple
Needs MRK P/S.
Implied fair value · at AMRN's multiple
Needs AMRN P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · MRK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AMARIN CORP PLC\UK · implied price per share
Bear
-$0.42
Base
-$0.49
Bull
-$0.56
Merck & Co., Inc. · implied price per share
Bear
$84.04
Base
$98.87
Bull
$113.70
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.22x
0.48x
Net debt / EBITDA
Leverage against operating earnings
6.57x
0.34x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$15.01B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
Pfizer Inc.
AMRN vs PFE
Johnson & Johnson
AMRN vs JNJ
Eli Lilly and Company
AMRN vs LLY
Bristol-Myers Squibb Company
AMRN vs BMY
AbbVie Inc.
AMRN vs ABBV
AMGEN INC
AMRN vs AMGN
$99.83M
$25.10B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe AMRN can rapidly restore positive growth and profitability enough to re-rate far above its current P/S and EV/Revenue multiples, then hold or consider the name; otherwise, the data supports avoiding it or reducing exposure because MRK-based valuation implies severe downside and fundamentals remain weak.
AMRN trades at a $15.24 current price versus a P/S-implied value of $2.34, implying 84.7% downside. The gap is driven by AMRN’s far richer sales multiple than MRK despite much weaker operating performance.
Supporting Metrics
